# EDGAR Filing Document

**Accession Number:** 0001677940
**File Stem:** 0001140361-23-011528
**Filing Date:** 2023-3
**Character Count:** 2854
**Document Hash:** a5ca8cc93f69e056a0c5626579ac1242
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-23-011528.hdr.sgml**: 20230314

**ACCESSION NUMBER**: 0001140361-23-011528

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230314

**FILED AS OF DATE**: 20230314

**DATE AS OF CHANGE**: 20230314

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BeyondSpring Inc.
- **CENTRAL INDEX KEY:** 0001677940
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38024
- **FILM NUMBER:** 23729270

**BUSINESS ADDRESS:**
- **STREET 1:** 28 LIBERTY STREET
- **STREET 2:** 39TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10005
- **BUSINESS PHONE:** 646-528-4184

**MAIL ADDRESS:**
- **STREET 1:** 28 LIBERTY STREET
- **STREET 2:** 39TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10005

### UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION <br> WASHINGTON, D.C. 20549

### FORM 6-K

#### REPORT OF FOREIGN PRIVATE ISSUER<br> PURSUANT TO RULE 13a-16 OR 15d-16<br> UNDER THE SECURITIES EXCHANGE ACT OF 1934

#### For the month of March 2023

#### Commission File Number: 001-38024

## BeyondSpring Inc.

#### BeyondSpring Inc.<br> 28 Liberty Street, 39th Floor<br> New York, New York 10005<br> (Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

------

Dalian Wanchunbulin Pharmaceuticals Ltd., the Chinese subsidiary of BeyondSpring Inc. (the "Company"), had withdrawn the New Drug Application submission of the indication of "Plinabulin in combination of pegfilgrastim agents to treat chemotherapy-induced neutropenia in adult non-myeloid cancer" from China National Medical Products Administration (the "NMPA"). The Company will continue to communicate with the NMPA regarding the re-filing of the CIN indication and will submit the application as soon as practically possible.

This Report on Form 6-K is incorporated by reference into the Registration Statements on Form F-3, File No. 333-257639 and File No. 333-249816, and the Registration Statements on Form S-8, File No. 333-216639 and File No. 333-240082, of the Company.

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | BeyondSpring Inc. | BeyondSpring Inc. |
|  | By: | /s/ Lan Huang |
|  | Name: Lan Huang | Name: Lan Huang |
|  | Title: Chairperson and Chief Executive Officer | Title: Chairperson and Chief Executive Officer |
| Date: March 14, 2023 |  |  |

---

------